Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

MKTP Surgery Has Long-Term Benefit For Restoring Skin Pigmentation In Vitiligo Patients

August 2, 2017 By Henry Ford Health System

A Henry Ford Hospital study has shown that skin transplant surgery has long-term benefit for restoring skin pigmentation caused by the skin disease vitiligo.

In a retrospective study, researchers found that a majority of areas of the skin treated with surgery still had “very good to excellent” color match pigmentation five years later.

Treated areas included the face, neck, hands, torso, legs, and feet. Skin type, age, and location of the vitiligo had no significant effect on the outcome of the repigmentation.

The surgery is known as melanocyte-keratinocyte transplantation or MKTP. During surgery, melanocyte skin cells responsible for giving color to the skin, hair, and eyes are harvested from healthy, pigmented areas of the body and transferred to an area that lost its pigment. Pigmentation starts to return to the surgery area in about two months.

The study is published in the Journal of the American Academy of Dermatology.

“MKTP works and it lasts a long time,” says Iltefat Hamzavi, MD, a Henry Ford dermatologist and the study’s senior author and principal investigator. “It’s better than any technology we have to treat this condition.”

This is vitiligo on the cheek of a Middle Eastern patient at baseline. Skin pigmentation restored at three months and 54 months post MKTP surgery. (Image credit: Henry Ford Hospital)

Vitiligo develops when melanocyte cells are killed by the body’s immune system, causing the area of the skin to turn white because the cells no longer make pigment. The white lesions vary in size and location — face, hands, arms, feet, and torso. It is more noticeable in people with darker skin.

The American Academy of Dermatology says millions of people are living with vitiligo worldwide.

Vitiligo has two types — segmental and nonsegmental. Segmental vitiligo appears on one segment, or part, of the body like the face or arm. Nonsegmental vitiligo is the most common type and appears on both sides of the body such as the hands and knees.

The skin disease is non-contagious and treatable — topical medication, light therapy, depigmentation, and skin grafting, among them. However, it’s emotionally stigmatizing for those living with it and often comes with awkward stares and impolite comments.

Henry Ford’s study is believed to be the first in the United States to evaluate MKTP’s long-term benefit. Researchers analyzed repigmentation results in 63 vitiligo patients who underwent MKTP between January 2009 and April 2014. Key highlights:

  • 71 percent repigmentation was maintained in 45 segmental vitiligo lesions five years after surgery.
  • 64 percent repigmentation was maintained in 90 nonsegmental vitiligo lesions five years after surgery.
  • 75 percent repigmentation was maintained in all vitiligo lesions at two, four and five years after surgery.

In 2009 Henry Ford became the first hospital in North America to perform MKTP. Its benchmark research published in the Archives of Dermatology found that MKTP was safe and effective for treating vitiligo, for which there is no cure. It also demonstrated the potential for restoring pigmentation – in eight patients with a specific type of vitiligo, the treated area regained on average 74 percent of its natural skin color after six months.

“We were the first North America center to show it works. Now we can show that not only does it work, it lasts for years in a majority of patients,” Hamzavi says.

Since the early years, Hamzavi and his team have refined MKTP’s technique to maximize the potential for repigmentation. Most notable is that a laser is now used for removing the white vitiligo lesions and prepping it to receive the healthy melanocyte cells. Previously, doctors used a dermabrader. Also, more superior dressings bring improved comfort to patients.

“If you pick the right patient, do the procedure properly — the majority of patients will maintain their color,” Hamzavi says of MKTP.

Related Articles Read More >

Avail Medsystems
How Avail Medsystems seeks to create a connected OR experience
Engineer inspecting artificial hip joint parts in quality control department in orthopaedic factory
Deburring and finishing for beautiful, functional medical devices
FDA logo
FDA seeking innovations to move beyond heater-cooler device problems
Logos of Creo Medical and Intuitive
Creo Medical inks collaboration agreement with Intuitive

DeviceTalks Weekly.

June 24, 2022
How innovative design, commercial strategy is building Cala Trio’s bioelectronic medicine market
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech